Search results for " TRANSPLANT"

showing 10 items of 1575 documents

Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transp…

2019

Abstract Chronic graft-versus-host disease (cGVHD) remains the leading cause of late morbidity and mortality. Despite the growing number of treatment options in cGVHD, evidence remains sparse. The German-Austrian-Swiss GVHD Consortium performed a survey on clinical practice in treatment of cGVHD among transplant centers in Germany, Austria, and Switzerland in 2009 and 2018 and compared the results. The survey performed in 2009 contained 20 questions on first-line treatment and related issues and 4 questions on second-line scenarios followed by a survey on all systemic and topic treatment options known and applied, with 31 of 36 transplant centers (86%) responding. The survey in 2018 repeate…

AdultMalemedicine.medical_specialtyRuxolitinibMedizinBronchiolitis obliteransGraft vs Host DiseaseDiseasechemistry.chemical_compoundPiperidinesGermanyNitrilesmedicineHumansIntensive care medicineBronchiolitis ObliteransImmunosuppressive treatmentImmunosuppression TherapyTransplantationbusiness.industryAdenineHematopoietic Stem Cell TransplantationHematologymedicine.diseaseClinical trialGraft-versus-host diseasePyrimidineschemistryIbrutinibAustriaChronic DiseasePyrazolesFemaleAllogeneic hematopoietic stem cell transplantbusinessSwitzerlandmedicine.drugBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
researchProduct

Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia

2019

We analyzed the outcomes of 26 consecutive patients with acquired severe aplastic anemia (SAA) undergoing peripheral blood stem cell transplantation (PBSCT) with partial ex vivo T cell depletion with a targeted T cell dose from HLA-identical sibling donors. The median patient age was 37 years (range, 3 to 63 years). Four patients with uncontrolled pneumonia at the time of transplantation died, on days +1, +2, +21, and +26. All evaluable patients engrafted, with a median time to neutrophil recovery of 11 days (range, 10 to 14 days) and a median time to platelet recovery of 19 days (range, 8 to 53 days). Two patients had transient grade I acute graft-versus-host disease (GVHD) with skin invol…

AdultMalemedicine.medical_specialtySevere aplastic anemiaAdolescentT-LymphocytesT cellGraft vs Host DiseaseHuman leukocyte antigenSeverity of Illness IndexGastroenterologyDisease-Free SurvivalLymphocyte DepletionHLA AntigensInternal medicinemedicineHumansCumulative incidenceSiblingChildAllogeneic stem cell transplantation Ex vivo T cell depletion Matched sibling donor Severe aplastic anemiaEx vivo T cell depletionMatched sibling donorPeripheral Blood Stem Cell TransplantationTransplantationbusiness.industryHistocompatibility TestingSiblingsAnemia AplasticHematologyMiddle AgedAllograftsmedicine.diseaseSevere Aplastic AnemiaTissue DonorsAllogeneic stem cell transplantationSurvival RateTransplantationPneumoniasurgical procedures operativemedicine.anatomical_structureChild PreschoolAcute DiseasebusinessEx vivoFollow-Up StudiesBiology of Blood and Marrow Transplantation
researchProduct

Bone Marrow Concentrate and Bovine Bone Mineral for Sinus Floor Augmentation

2011

Purpose: The purpose of this work was to evaluate the potential of substituting autogenous bone (AB) by bone marrow aspirate concentrate (BMAC). Both AB and BMAC were tested in combination with a bovine bone mineral (BBM) for their ability of new bone formation (NBF) in a multicentric, randomized, controlled, clinical and histological noninferiority trial.Materials and Methods: Forty-five severely atrophied maxillary sinus from 26 patients were evaluated in a partial cross-over design. As test arm, 34 sinus of 25 patients were augmented with BBM and BMAC containing mesenchymal stem cells. Eleven control sinus from 11 patients were augmented with a mixture of 70% BBM and 30% AB. Biopsies wer…

AdultMalemedicine.medical_specialtySinus Floor AugmentationOSTEOGENIC DIFFERENTIATIONBone RegenerationMaxillary sinusBiomedical EngineeringSinus Floor AugmentationBioengineeringBiochemistryMAXILLARY SINUSlaw.inventionMESENCHYMAL STEM-CELLSBIO-OSSBiomaterialsRandomized controlled trialTISSUE-ENGINEERED BONEBone MarrowOsteogenesislawmedicineAnimalsHumansSingle-Blind MethodSinus (anatomy)AgedIMPLANT PLACEMENTHYDROXYAPATITE CERAMICSBone TransplantationIntention-to-treat analysisPOROUS HYDROXYAPATITEbusiness.industryIN-VITROMiddle AgedSurgeryAUTOGENOUS BONEImplant placementBovine bonemedicine.anatomical_structureBone SubstitutesCattleFemaleBone marrowbusinessTissue Engineering. Part A
researchProduct

Enhanced Recovery after Implementation of Surgery Protocol in Living Kidney Donors: The ISMETT Experience

2019

Abstract Introduction Laparoscopic living donor nephrectomy (LLDN) has become the standard procedure for living kidney transplantation. Enhanced recovery after surgery (ERAS) is a multimodal perioperative management aimed at facilitating rapid patient recovery after major surgery by modifying the response to stress induced by exposure to surgery. This association can further reduce hospital stay, surgical stress, and perioperative morbidity of living kidney donors. Material and methods In this retrospective analysis conducted at our institute, we compared the first 21 patients who underwent LLDN enrolled with the ERAS protocol with 55 patients who underwent LLDN with the fast-track protocol…

AdultMalemedicine.medical_specialtySurgical stressNephrectomyPatient ReadmissionPostoperative ComplicationsEnhanced recoveryISMETTLiving DonorsMedicineHumansKidney transplantationAgedRetrospective StudiesProtocol (science)TransplantationKidneybusiness.industryRetrospective cohort studyPerioperativeRecovery of FunctionLength of StayMiddle Agedmedicine.diseaseKidney TransplantationSurgerymedicine.anatomical_structureTissue and Organ HarvestingSurgeryFemaleLaparoscopybusiness
researchProduct

A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine

2005

In this randomized trial renal transplant recipients were treated with basiliximab, everolimus 3 mg/day, low-dose CsA. At transplantation, patients were randomized to stop steroids at the seventh day (group A) or to continue oral steroids in low doses (group B). Of the 113 patients enrolled, 65 were randomized to group A and 68 to group B. All patients were followed for 2 years. During the study 28 (43%) group A patients required reintroduced corticosteroids. One patient died, in group B. The Graft survival rate was 97% in group A and 90% in group B. There were more biopsy-proven rejections in group A (32% vs 16%; P = .044). The mean creatinine clearance was 54 +/- 21 mL/min in group A vs 5…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentBasiliximabUrologyRenal functionGroup AGroup Blaw.inventionRandomized controlled triallawAdrenal Cortex HormonesHLA AntigensmedicineLiving DonorsHumansEverolimuscyclosporineAgedSirolimusTransplantationEverolimusbusiness.industryHistocompatibility TestingeverolimuMiddle Agedrenal transplantationKidney TransplantationSurgerySteroid Avoidance in Renal Transplant PatientsTransplantationRegimentrial; transplant; immunosoppressivesteroid avoidanceSurgeryFemalebusinessImmunosuppressive Agentsmedicine.drugFollow-Up Studies
researchProduct

Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients

2015

Cardiovascular (CV) events represent major impediments to the long-term survival of liver transplantation (LT) patients. The aim of this study was to assess whether the Framingham risk score (FRS) at transplantation can predict the development of post-LT cardiovascular events (CVEs). Patients transplanted between 2006 and 2008 were included. Baseline features, CV risk factors, and CVEs occurring after LT (ischemic heart disease, stroke, heart failure, de novo arrhythmias, and peripheral arterial disease) were recorded. In total, 250 patients (69.6% men) with a median age of 56 years (range, 18-68 years) were included. At transplantation, 34.4%, 34.4%, and 33.2% of patients, respectively, ha…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentRenal functionKaplan-Meier EstimateLiver transplantationKidneyRisk AssessmentGastroenterologyYoung AdultRisk FactorsInternal medicinemedicineHumansAgedProportional Hazards ModelsRetrospective StudiesTransplantationUnivariate analysisFramingham Risk ScoreHepatologybusiness.industryProportional hazards modelHazard ratioHepatitis CMiddle Agedmedicine.diseaseHepatitis CTransplant RecipientsLiver TransplantationSurgeryTransplantationLogistic ModelsTreatment OutcomeCardiovascular DiseasesSpainMultivariate AnalysisFemaleKidney DiseasesSurgerybusinessGlomerular Filtration Rate
researchProduct

Characteristics, Trends, and Outcomes of Liver Transplantation for Primary Sclerosing Cholangitis in Female Versus Male Patients

2021

Background. The influence of sex on primary sclerosing cholangitis (PSC), pre- and postliver transplantation (LT) is unclear. Aims are to assess whether there have been changes in incidence, profile, and outcome in LT-PSC patients in Europe with specific emphasis on sex. Methods. Analysis of the European Liver Transplant Registry database (PSC patients registered before 2018), including baseline demographics, donor, biochemical, and clinical data at LT, immunosuppression, and outcome. Results. European Liver Transplant Registry analysis (n = 6463, 32% female individuals) demonstrated an increasing number by cohort (1980-1989, n = 159; 1990-1999, n = 1282; 2000-2009, n = 2316; 2010-2017, n =…

AdultMalemedicine.medical_specialtyTime FactorsDatabases Factualmedicine.medical_treatmentCholangitis SclerosingPopulation030230 surgeryLiver transplantationRisk AssessmentPrimary sclerosing cholangitis03 medical and health sciencesSex Factors0302 clinical medicineRisk FactorsInternal medicinemedicineHumansRegistriesHealthcare DisparitieseducationTransplantationeducation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)Graft SurvivalImmunosuppressionHealth Status DisparitiesMiddle Agedmedicine.diseaseLiver TransplantationEuropeTransplantationTreatment OutcomeMale patientCohortFemale030211 gastroenterology & hepatologybusinessTransplantation
researchProduct

Lung Preservation With Perfadex or Celsior in Clinical Transplantation: A Retrospective Single-Center Analysis of Outcomes.

2015

BACKGROUND Despite improvement of lung preservation by the introduction of low-potassium dextran (LPD) solution, ischemia-reperfusion injury remains a major contributor to early post-lung transplant graft dysfunction and mortality. After favorable experimental data, Celsior solution was used in our clinical lung transplant program. Data were compared with our historic LPD cohort. METHODS Between January 2002 and January 2005, 209 consecutive lung transplantations were performed with LPD. These were compared to 208 transplants between February 2005 and September 2007 with Celsior. Endpoints included posttransplant PaO2/FiO2 ratio at different timepoints after intensive care unit (ICU) admiss…

AdultMalemedicine.medical_specialtyTime FactorsOrgan Preservation SolutionsBronchiolitis obliteransKaplan-Meier EstimateSingle CenterDisaccharidesDisease-Free Survivallaw.inventionElectrolytesGlutamateslawRisk FactorsGermanymedicineHumansHistidineMannitolCitratesProportional Hazards ModelsRetrospective StudiesTransplantationLungProportional hazards modelbusiness.industryRetrospective cohort studyOrgan PreservationLength of StayMiddle Agedmedicine.diseaseIntensive care unitGlutathioneRespiration ArtificialSurgeryTransplantationIntensive Care Unitsmedicine.anatomical_structureTreatment OutcomeCohortBronchiolitisFemalePrimary Graft DysfunctionbusinessLung TransplantationTransplantation
researchProduct

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell glo…

2011

Abstract Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before transplantation from unrelated donors. The cumulative incidence of extensive cGVHD after 3 years was 12.2% in the ATG-F group versus 45.0% in the control group (P < .0001). The 3-year cumulative incidence of relapse and of nonrelapse mortality was 32.6% and 19.4% in the ATG-F group and 28.2% and 33.5% in the contr…

AdultMalemedicine.medical_specialtyTime FactorsTransplantation ConditioningAdolescentmedicine.medical_treatmentImmunologyMedizinGraft vs Host DiseaseHematopoietic stem cell transplantationBiochemistryGastroenterologyDisease-Free Survivallaw.inventionRandomized controlled triallawRecurrenceInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceSurvival rateAntilymphocyte SerumImmunosuppression Therapybusiness.industryIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryTransplantationSurvival RateGraft-versus-host diseaseMethotrexateHematologic NeoplasmsChronic DiseaseCyclosporineFemalebusinessImmunosuppressive AgentsBlood
researchProduct

Psychological Conflicts Between Relatives During the Long-Term Course After Successful Living Organ Donation

2008

The German transplantation law prefers living organ donation between close relatives and spouses, which is assumed to guarantee unequivocal altruistic motivation. Since 2001, 68 recipient-donor-pairs, who aspired to have a renal or liver transplantation, underwent a systematic psychosomatic evaluation. Meanwhile, 43 transplantations were performed including 34 renal and 9 liver cases. Seventeen recipient-donor-pairs were readministered evaluations by the department of psychosomatic medicine after 1 to 6 years after transplantation for long-term follow-up. In 10 cases of medically successful transplantation, we identified severe conflicts between donor, recipient, and next-of-kin. Major conf…

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentFamily conflictStalemateLiver transplantationNephrectomyConflict PsychologicalInterviews as TopicInterpersonal relationshipLiving organ donationLiving DonorsmedicineHepatectomyHumansFamilyInterpersonal RelationsOrgan donationSpousesTransplantationbusiness.industryPsychosomatic medicineMiddle AgedSurgeryTransplantationFamily medicineFemaleSurgerybusinessFollow-Up StudiesTransplantation Proceedings
researchProduct